Neurotech International

Quarterly Activities Report
for the period ending 30 September 2026

Neurotech International Limited (ASX: NTI) ("Neurotech" or "the Company"), a clinical-stage biopharmaceutical company focused on paediatric neurological disorders, is pleased to present its activities report for the quarter ended 30 September 2026 (Q1 FY2027), together with its Appendix 4C Quarterly Cash Flow Report.

During the quarter, Neurotech dosed the first patient in its pivotal Phase 3 "Beyond Harmony" clinical trial of NTI164 in children with autism spectrum disorder (ASD). All Australian trial sites were initiated, with up to 200 patients planned for enrolment under an adaptive trial design. The commencement of dosing advances NTI164 into pivotal Phase 3 clinical development, supporting the Company's objective of regulatory registration and commercialisation as a potential treatment for the core symptoms of ASD.

The Company also received US Food and Drug Administration (FDA) clearance of its Investigational New Drug (IND) submission and Notices of Allowance from the United States Patent and Trademark Office (USPTO) for two patent applications. Results from the Phase II/III "Harmony" study were published in the peer-reviewed journal Neurotherapeutics, adding to the clinical evidence supporting the Phase 3 program.

The Company also received $3.15 million through a loan secured against anticipated research and development tax incentive offsets and secured binding commitments for a placement of approximately $4.5 million before costs. These funding initiatives support the Company's Phase 3 "Beyond Harmony" clinical trial, regulatory activities and working capital requirements. Based on its current clinical development plan and budget, the Company anticipates to be fully funded through to the top line data readout of the Phase 3 clinical trial.

Neurotech's principal operational focus is the execution of Beyond Harmony, which is designed to generate pivotal efficacy and safety data to support the Company's broader global registration and commercialisation strategy for NTI164.

First patient dosed in Phase 3 Beyond Harmony autism trial

On 21 September 2026, Neurotech announced that the first patient had been dosed in its pivotal Phase 3 Beyond Harmony clinical study evaluating NTI164 in paediatric patients with ASD. All six sites across Victoria, Queensland, New South Wales, Tasmania and Western Australia have been initiated.

The national, multi-centre, randomised, double-blind, placebo-controlled study is designed to evaluate the efficacy, safety and tolerability of NTI164 in children with Autism Spectrum Disorder (ASD). The study will assess key behavioural and functional outcomes, with a particular focus on core ASD symptoms, while also investigating the neuroinflammatory pathways associated with the disorder. Clinical endpoints will be aligned with relevant regulatory guidance to support the ongoing development of NTI164.

The trial is expected to enrol up to 200 patients and will incorporate an adaptive design, allowing for pre-specified adjustments based on interim analyses while preserving the scientific rigour and statistical integrity of the study.

At the time of this announcement, Neurotech had received more than 300 enquiries from parents and caregivers seeking information about potential participation following media coverage of the trial.

This level of interest provided the Company with confidence in its ability to recruit the required participants within the planned recruitment timeframe.

Beyond Harmony builds on the clinical evidence generated in the 54-patient Phase II/III Harmony study, which reported clinically meaningful and statistically significant results across a range of validated measures, supported by a favourable safety profile. These data formed part of the clinical evidence included in Neurotech's FDA-cleared IND application.

Neurotech receives FDA IND clearance

The FDA cleared Neurotech's IND submission for NTI164, authorising the Company to commence its proposed clinical development program in the United States. The submission included chemistry, manufacturing and controls (CMC), non-clinical and clinical information supporting the proposed program.

Should Neurotech elect to commence clinical development in the United States, the study conducted under the FDA-cleared IND would comprise a comprehensive population pharmacokinetic (PopPK) program. This program has been designed to complement the Australian Phase 3 Beyond Harmony trial by generating pharmacokinetic data to support dose characterisation and future product registration initiatives.

The Australian Phase 3 clinical trial results are expected to form an important component of the global clinical evidence package supporting future regulatory submissions. Together with the proposed US PopPK study, the programs are intended to provide an integrated efficacy, safety and pharmacokinetic data package for NTI164.

In parallel, Neurotech is engaging with the Australian Therapeutic Goods Administration (TGA) to support alignment of its Australian and US regulatory strategies and the potential use of clinical data across multiple jurisdictions.

The IND clearance establishes a formal US clinical development pathway and supports the Company's broader commercialisation strategy and discussions with potential strategic partners.

Notices of Allowance secured for two US patent applications

During the quarter, Neurotech received Notices of Allowance from the USPTO for US patent applications No. 18/698,605 and No. 19/335,945. Both applications are titled "Compositions and Methods for Treating Neurological Disorders" and relate to key aspects of NTI164.

The allowed claims of US patent application No. 18/698,605 cover methods of reducing neuroinflammation using NTI164, while the allowed claims of US patent application No. 19/335,945 are specifically directed to methods of treating ASD.

Harmony study results published in Neurotherapeutics

In July, results from Neurotech's Phase II/III Harmony study of NTI164 in children with ASD were accepted for publication in Neurotherapeutics, the official journal of the American Society for Experimental Neurotherapeutics. The paper was subsequently published, as confirmed in the Company's September update on the commencement of Beyond Harmony (ASX Announcement: 21/09/2026).

The paper, titled "NTI164, a novel medicinal cannabis extract, improves core symptoms of autism spectrum disorder: Results from a double-blind, randomised, controlled trial (The Harmony Study)", reports findings from the Company's NTIASD2 clinical trial.

The randomised, double-blind, placebo-controlled study evaluated the efficacy and safety of NTI164 in 54 children aged two to 17 years with ASD. The study generated clinically meaningful and statistically significant results across a range of validated measures, supported by a favourable safety profile.

Publication followed independent peer review of the study methodology, analysis and findings, providing further external scientific scrutiny of Neurotech's clinical development program.

The publication adds to the body of peer-reviewed NTI164 data across paediatric neurological indications, including clinical and mechanistic findings in Paediatric Acute-Onset Neuropsychiatric Syndrome (PANS / Paediatric Autoimmune Neuropsychiatric Disorders Associated with Streptococcal Infections (PANDAS) and an earlier paper in Rett Syndrome.

Fundraising activities

In August, Neurotech announced binding commitments from existing and new institutional and sophisticated investors for a placement of approximately $4.5 million before costs, comprising approximately 321.4 million new fully paid ordinary shares at an issue price of $0.014 per share.

The placement was structured in two tranches, comprising approximately $4.1 million under the Company's existing placement capacity and approximately $0.4 million subject to shareholder approval. Taylor Collison Limited and Canary Capital Pty Ltd acted as Joint Lead Managers.

Placement proceeds are intended predominantly to fund the Phase 3 Beyond Harmony trial, as well as regulatory activities, general working capital and placement costs. At the time of the announcement, and subject to completion of the placement, Neurotech expected the net proceeds, together with existing cash, to fund the Company through to topline data readout from the Phase 3 trial, based on its clinical development plan and budget.

Furthermore, Neurotech entered into a secured loan agreement with Rockford RDF Pty Ltd as trustee for the Rockford RDF Unit Trust and received $3.15 million in funding secured against the Company's anticipated refundable R&D tax incentive offsets for FY2026 and FY2027.

The loan provides non-dilutive funding to support the Company's Phase 3 clinical studies in ASD, ongoing research and development activities and general working capital.

The facility carries an interest rate of 16% per annum and a capitalised establishment fee of 1%. It matures on 31 December 2027, subject to an extension option, and is expected to be repaid in two tranches from the Company's FY2026 and FY2027 refundable R&D tax incentive offsets. For further information, refer to the Company's announcement dated 15 July 2026.

Appendix 4C Commentary

During the quarter, the Company recorded total cash operating expenses (excluding revenue sources) of ~$4.1 million (Q4 FY2026: $1.9 million), consisting of research and development costs of ~$3.9 million (Q4 FY2026: $1.7 million), along with advertising, marketing, staff, administrative, and corporate costs of ~$0.2 million (Q4 FY2026: $0.2 million).

Research and development expenditure was driven by continued investment in IND-enabling preclinical development and toxicology programs to support regulatory submissions to the US FDA and Australian TGA.

Clinical expenditure focused on supporting the planning, preparation and implementation of the multi-centre Phase 3 clinical trial in paediatric ASD.

Further expenditure was directed towards drug product manufacturing and process optimisation, quality assurance and stability programs, and preclinical formulation development, supporting the broader clinical development and regulatory strategy for NTI164.

Total operating cash outflows for the quarter were ~$4.1 million (Q4 FY2026: cash outflows of $1.9 million).

The Company closed the quarter with cash and cash equivalents of ~$5.2 million (Q4 FY26: $2.4 million).

Further, payments to related parties and their associates as detailed in Section 6 of the Appendix 4C totalled $299,000.

Authority

This announcement has been authorised for release by the Board of Neurotech International Limited.

For further information contact us via info@neurotechinternational.com

About Neurotech

Neurotech International Limited (ASX:NTI) is a clinical-stage biopharmaceutical development company focused predominantly on paediatric neurological disorders with a broad-spectrum oral cannabinoid drug therapy called NTI164. Neurotech has commenced dosing on a pivotal Phase III trial in Autism Spectrum Disorder (ASD) after successfully completing a Phase II/III randomised, double-blind, placebo-controlled clinical trial in ASD with clinically meaningful and statistically significant benefits reported across a number of clinically-validated measures and excellent safety. In addition, Neurotech has completed and reported statistically significant and clinically meaningful Phase I/II trials in ASD, Paediatric Autoimmune Neuropsychiatric Disorders Associated with Streptococcal Infections (PANDAS) and Paediatric Acute-Onset Neuropsychiatric Syndrome (PANS), collectively PANDAS/PANS along with Rett Syndrome. Neurotech has received human ethics committee clearance for a Phase I/II clinical trial in spastic cerebral palsy.

For more information about Neurotech please visit http://www.neurotechinternational.com.

Appendix 4C

Quarterly cash flow report for entities subject to Listing Rule 4.7B

Name of entity

Neurotech International Limited

ABN	**Quarter ended ("current quarter")**
73 610 205 402	30 September 2026

Consolidated statement of cash flows		**Current quarter $A'000**	**Year to date (3 months) $A'000**
1.	**Cash flows from operating activities**		
1.1	Receipts from customers	0	0
1.2	Payments for		
	(a) research and development	(3,928)	(3,928)
	(b) product manufacturing and operating costs	0	0
	(c) advertising and marketing	(34)	(34)
	(d) leased assets	0	0
	(e) staff costs	(171)	(171)
	(f) administration and corporate costs	(82)	(82)
1.3	Dividends received (see note 3)	0	0
1.4	Interest received	27	27
1.5	Interest and other costs of finance paid	(1)	(1)
1.6	Income taxes paid	0	0
1.7	Government grants and tax incentives (R&D Rebate)	0	0
1.8	Other (GST refunds)	0	0
1.9	**Net cash from / (used in) operating activities**	**(4,189)**	**(4,189)**

2.	**Cash flows from investing activities**		
2.1	Payments to acquire or for:		
	(a) entities	0	0
	(b) businesses	0	0
	(c) property, plant and equipment	0	0
	(d) investments	0	0
	(e) intellectual property	0	0

Consolidated statement of cash flows		Current quarter $A'000	Year to date (3 months) $A'000
	(f) other non-current assets	0	0
2.2	Proceeds from disposal of:		
	(a) entities	0	0
	(b) businesses	0	0
	(c) property, plant and equipment	0	0
	(d) investments	0	0
	(e) intellectual property	0	0
	(f) other non-current assets	0	0
2.3	Cash flows from loans to other entities	0	0
2.4	Dividends received (see note 3)	0	0
2.5	Other (provide details if material)	0	0
2.6	**Net cash from / (used in) investing activities**	**0**	**0**

3.	**Cash flows from financing activities**		
3.1	Proceeds from issues of equity securities (excluding convertible debt securities)	4,107	4,107
3.2	Proceeds from issue of convertible debt securities	0	0
3.3	Proceeds from exercise of options	0	0
3.4	Transaction costs related to issues of equity securities or convertible debt securities	(284)	(284)
3.5	Proceeds from borrowings	3,150	3,150
3.6	Repayment of borrowings	0	0
3.7	Transaction costs related to loans and borrowings	0	0
3.8	Dividends paid	0	0
3.9	Other (provide details if material)	0	0
3.10	**Net cash from / (used in) financing activities**	**6,973**	**6,973**

4.	**Net increase / (decrease) in cash and cash equivalents for the period**		
4.1	Cash and cash equivalents at beginning of period	2,414	2,414
4.2	Net cash from / (used in) operating activities (item 1.9 above)	(4,189)	(4,189)
4.3	Net cash from / (used in) investing activities (item 2.6 above)	0	0

Consolidated statement of cash flows		Current quarter $A'000	Year to date (3 months) $A'000
4.4	Net cash from / (used in) financing activities (item 3.10 above)	6,973	6,973
4.5	Effect of movement in exchange rates on cash held	0	0
4.6	**Cash and cash equivalents at end of period**	**5,198**	**5,198**

5.	**Reconciliation of cash and cash equivalents** at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts	**Current quarter $A'000**	**Previous quarter $A'000**
5.1	Bank balances	1,683	899
5.2	Call deposits	3,515	1,515
5.3	Bank overdrafts	0	0
5.4	Other (provide details)	0	0
5.5	**Cash and cash equivalents at end of quarter (should equal item 4.6 above)**	**5,198**	**2,414**

6.	**Payments to related parties of the entity and their associates**	**Current quarter $A'000**
6.1	Aggregate amount of payments to related parties and their associates included in item 1	299
6.2	Aggregate amount of payments to related parties and their associates included in item 2	0
	Payments at section 6. relate to director fees ($96,000), executive salaries ($170,000) and reimbursement ($33,000).	

7.	**Financing facilities** *Note: the term "facility' includes all forms of financing arrangements available to the entity.* *Add notes as necessary for an understanding of the sources of finance available to the entity.*	**Total facility amount at quarter end $A'000**	**Amount drawn at quarter end $A'000**
7.1	Loan facilities	0	0
7.2	Credit standby arrangements	0	0
7.3	Other (Loan against R&D Rebate)	3,150	3,150
7.4	**Total financing facilities**	3,150	3,150
7.5	**Unused financing facilities available at quarter end**		0

7.6 Include in the box below a description of each facility above, including the lender, interest rate, maturity date and whether it is secured or unsecured. If any additional financing facilities have been entered into or are proposed to be entered into after quarter end, include a note providing details of those facilities as well.

Neurotech entered into a secured loan agreement with Rockford RDF Pty Ltd as trustee for the Rockford RDF Unit Trust and received $3.15 million in July 2026. The loan was secured against the Company's anticipated refundable R&D tax incentive offsets for FY2026 and FY2027.

The facility carries an interest rate of 16% per annum and a capitalised establishment fee of 1%. It matures on 31 December 2027, subject to an extension option, and is expected to be repaid in two tranches from the Company's FY2026 and FY2027 refundable R&D tax incentive offsets. For further information, refer to the Company's announcement dated 15 July 2026.

8.	**Estimated cash available for future operating activities**	**$A'000**
8.1	Net cash from / (used in) operating activities (item 1.9)	4,189
8.2	Cash and cash equivalents at quarter end (item 4.6)	5,198
8.3	Unused finance facilities available at quarter end (item 7.5)	-
8.4	Total available funding (item 8.2 + item 8.3)	5,198
8.5	**Estimated quarters of funding available (item 8.4 divided by item 8.1)**	1.24

Note: if the entity has reported positive net operating cash flows in item 1.9, answer item 8.5 as "N/A". Otherwise, a figure for the estimated quarters of funding available must be included in item 8.5.

8.6 If item 8.5 is less than 2 quarters, please provide answers to the following questions:

8.6.1 Does the entity expect that it will continue to have the current level of net operating cash flows for the time being and, if not, why not?

The Company expects the level of net operating cash outflows to reduce from Q2FY27 to ongoing quarters. The Company paid a large amount of clinical trial initiation fees in Q1FY27 which were one off payments.

8.6.2	Has the entity taken any steps, or does it propose to take any steps, to raise further cash to fund its operations and, if so, what are those steps and how likely does it believe that they will be successful?
	The Company is expecting to receive funds from the second tranche of the placement that was announced in Q1FY27 and for which firm commitments have been received. The company is also expecting to receive further funds from its RDTI refund expected in Q2FY27 net of debt repayment. The Company continues to monitor its funding position and expenditure requirements closely.
8.6.3	Does the entity expect to be able to continue its operations and to meet its business objectives and, if so, on what basis?
	Yes, refer to the responses to questions 8.6.1 and 8.6.2.

Note: where item 8.5 is less than 2 quarters, all of questions 8.6.1, 8.6.2 and 8.6.3 above must be answered.

Compliance statement

1 This statement has been prepared in accordance with accounting standards and policies which comply with Listing Rule 19.11A.

2 This statement gives a true and fair view of the matters disclosed.

Date: 28 October 2026
.....

Authorised by: The Board of Directors
.....
(Name of body or officer authorising release – see note 4)

Notes

1. This quarterly cash flow report and the accompanying activity report provide a basis for informing the market about the entity's activities for the past quarter, how they have been financed and the effect this has had on its cash position. An entity that wishes to disclose additional information over and above the minimum required under the Listing Rules is encouraged to do so.

2. If this quarterly cash flow report has been prepared in accordance with Australian Accounting Standards, the definitions in, and provisions of, *AASB 107: Statement of Cash Flows* apply to this report. If this quarterly cash flow report has been prepared in accordance with other accounting standards agreed by ASX pursuant to Listing Rule 19.11A, the corresponding equivalent standard applies to this report.

3. Dividends received may be classified either as cash flows from operating activities or cash flows from investing activities, depending on the accounting policy of the entity.

4. If this report has been authorised for release to the market by your board of directors, you can insert here: "By the board". If it has been authorised for release to the market by a committee of your board of directors, you can insert here: "By the [*name of board committee – eg Audit and Risk Committee*]". If it has been authorised for release to the market by a disclosure committee, you can insert here: "By the Disclosure Committee".

5. If this report has been authorised for release to the market by your board of directors and you wish to hold yourself out as complying with recommendation 4.2 of the ASX Corporate Governance Council's *Corporate Governance Principles and Recommendations*, the board should have received a declaration from its CEO and CFO that, in their opinion, the financial records of the entity have been properly maintained, that this report complies with the appropriate accounting standards and gives a true and fair view of the cash flows of the entity, and that their opinion has been formed on the basis of a sound system of risk management and internal control which is operating effectively.